Episode 2, series 1. How I treat HER-2 positive ER/PR negative early breast cancer
Dr Abi Jenner discusses how she treats HER-2 positive ER/PR negative early breast cancer, including the use of trantuzumab, pertuzumab, and kadcyla, as well the role of neoadjuvant treatment to facilitate breast conserving surgery and how she manages patients requiring this.
The Bristol Oncology Podcasts's podcast
How I treat HER-2 positive ER/PR negative early breast cancer
References
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Prof Helena M Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, et al
Lancet VOLUME 393, ISSUE 10191, P2599-2612, JUNE 29, 2019
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, M.D., Chiun-Sheng Huang, M.D., Ph.D., Max S. Mano, M.D., Ph.D., Sibylle Loibl, M.D., Eleftherios P. Mamounas, M.D., Michael Untch, M.D., Ph.D., Norman Wolmark, M.D., Priya Rastogi, M.D., Andreas Schneeweiss, M.D., Andres Redondo, M.D., Ph.D., Hans H. Fischer, M.D., William Jacot, M.D., Ph.D., et al., for the KATHERINE Investigators
NEJM 2019; 380:617-628
View Online
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni , Tadeusz Pienkowski , Young-Hyuck Im , Ling-Ming Tseng , Mei-Ching Liu , Ana Lluch , Elżbieta Starosławska , Juan de la Haba-Rodriguez , Seock-Ah Im , Jose Luiz Pedrini , Brigitte Poirier, Paolo Morandi, Vladimir Semiglazov, Vichien Srimuninnimit, Giulia Valeria Bianchi , Domenico Magazzi, Virginia McNally , Hannah Douthwaite, Graham Ross, Pinuccia Valagussa
Lancet Oncol . 2016 Jun;17(6):791-800
The NHS PREDICT tool can be found at this link